×
Log in
Upload File
Most Popular
Study
Business
Design
Technology
Travel
Explore all categories
The top documents tagged [tyrosine kinase inhibitor]
Part 8
20 views
Nuovi inibitori irreversibili di EGFR Cesare Gridelli Division of Medical Oncology “S.G. Moscati” Hospital – Avellino (Italy)
[email protected]
[email protected]
212 views
1 Conflicts of interest Bernard Lo, M.D. September 16, 2010
217 views
Chronic Myelogenous Leukemia
51 views
Reference reagents for monitoring minimal residual disease
37 views
Difficult thyroid cancer cases
49 views
Targeting Chaperone Dependence in Rhabdomyosarcoma
91 views
Friedrich Overkamp 1. GEPARQUINTO (neoadjuvant) N=30 (21+9) GEPARQUINTO (neoadjuvant) N=30 (21+9) TEACH (Lapatinib adjuvant) N=8 TEACH (Lapatinib adjuvant)
223 views
Comprehensive Genomic Profiling of Breast Cancer By Massively Parallel Sequencing Reveals New Routes To Targeted Therapies JS Ross, CE Sheehan A Parker,
216 views
< Prev